Omar Castaneda Puglianini, MD

Cancer Focus:
Multiple Myeloma-Plasma Cell Disorders

Dr. Castaneda Puglianini is an Associate Member at the Department of Blood and Marrow Transplant and Cellular Immunotherapy (BMT CI) and the Medical Director of the “Specialized Oncology Non-cellular Immunotherapy Comprehensive Care Service” - SONIC - at the H. Lee Moffitt Cancer Center and Research Institute and an Associate Professor in the Department of Oncologic Sciences at the University of South Florida. He earned his MD from Universidad Peruana Cayetano Heredia in Lima, Peru, and completed an Internal Medicine residency at Albert Einstein College of Medicine in New York. He completed a Hematology/Oncology fellowship at Virginia Commonwealth University/Massey Comprehensive Cancer Center followed by a Blood and Marrow Transplant and Cellular Immunotherapy fellowship at Moffitt Cancer Center. Dr. Castaneda Puglianini has previously served as the Director of the CAR T-cell Therapy Program at the Division of Hematology/Oncology and Palliative Care at VCU Massey Comprehensive Cancer Center. Dr. Castaneda Puglianini's clinical interests are in the treatment of hematological malignancies with a focus on plasma cell neoplasms using modalities such as autologous and allogeneic hematopoietic stem cell transplantation as well as adoptive cellular and non-cellular immunotherapy. His research areas of interest include prognostic factors associated with progression, the role of minimal residual disease (MRD) and clinical trials investigating novel cellular immunotherapeutic approaches for multiple myeloma.

Education & Training

Board Certification:

• Internal Medicine - Hematology
• Internal Medicine - Medical Oncology
• Internal Medicine -

Fellowship:

• Virginia Commonwealth University Massey Cancer Center - Hematology and Oncology
• H. Lee Moffitt Cancer Center and Research Institute - Blood and Marrow Transplantation

Residency:

• Albert Einstein College of Medicine Jacobi Medical Center - Internal Medicine

Medical School:

• Universidad Peruana Cayetano Heredia Alberto Hurtado School of Medicine - MD

• Hansen DK, Castaneda Puglianini OA, Grajales-Cruz A, Nagar SP, Ghosh S, Alegria V, De Braganca KC, Lengil T, Sharma M, Pai H, Perciavalle M, Maitland J, Emond B, Bixby T, Qureshi ZP, Janakiram M. Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma. Clin Epidemiol. 2026 May.18:615866. Pubmedid: 42227005. Pmcid: PMC13222586.
• Davis JA, McElwee J, Gonzalez R, Julian K, Nachar VR, Snyder J, Mahmoudjafari Z, Granger K, Warrick M, Smith D, Baek G, Huang I, Portuguese A, Dima D, Banerjee R, Atrash S, Sborov DW, Grajales-Cruz A, Puglianini OC, Dominick A, Hansen DK, Elsey G, Moore DC. Safety of MMR vaccination for patients with myeloma receiving daratumumab after autologous stem cell transplantation. Blood Neoplasia. 2026 May.3(2):100220. Pubmedid: 42007251. Pmcid: PMC13091426.
• Portuguese AJ, Davis JA, Raza S, Castaneda Puglianini O, Freeman C, Alsina M, Wright C, Blue BJ, Baz RC, Shain KH, Goel U, Khouri J, Anwer F, Ali HM, Pasvolsky O, Gaballa M, Patel K, Garcia-Pleitez H, Mikulski D, Fogel L, Zolotov E, Sannareddy A, Afrough A, Anderson LD, Julian K, Dima D, Banerjee R, Liang EC, Cassano Cassano R, Herr MM, Hassan H, Shune L, Kort J, Midha S, Nadeem O, Sidana S, Lin Y, Locke FL, Hansen DK, Sborov D, Biran N, Grajales-Cruz A. Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J. 2026 Mar.16(1). Pubmedid: 41896552. Pmcid: PMC13039266.
• Oswald LB, Li X, Ferraris CE, DeAvila G, Scheiber-Camoretti D, Gudenkauf LM, Small BJ, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Crowder SL, Parker N, Carson TL, Vinci CE, Baz RC, Shain KH, Blue BJ, Grajales-Cruz AF, Matte K, Kale B, Kaldas D, Perna F, Alsina M, Freeman CL, Castaneda Puglianini OA, Nishihori T, Liu HD, Locke FL, Jim HS, Hansen DK, Peres LC. Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity. Blood Adv. 2026 Mar.10(6):1959-1963. Pubmedid: 41564433. Pmcid: PMC12995473.
• Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R, Perciavalle M, De Wiest D, Huo S, Lee S, Qureshi ZP, Jagannath S. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2026 Mar.26(3):369-378. Pubmedid: 41734332.
• Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ. Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium. Blood Cancer J. 2026 Mar.16(1). Pubmedid: 41862439. Pmcid: PMC13018517.
• Joshi U, Ong F, Melzer D, Ma JC, Saltos A, Chiappori A, Creelan B, Pellini B, Lu C, Haura E, Shafique M, Tanvetyanon T, Kareem SS, Budhathoki P, Solarte DCB, Naqvi SMH, Puglianini OC, Gaballa S, Gray JE, Puri S. Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use. Clin Lung Cancer. 2026 Mar.27(2):48-58. Pubmedid: 41544604.
• Noble JD, Peixoto BC, Menges MA, Abraham-Miranda J, Savid-Frontera C, Sawyer W, Sorathia VD, Cuadrado Delgado LA, Corallo SA, Llanos JC, Merritt EC, De Avila G, Castaneda-Puglianini OA, Liu HD, Alsina M, Nishihori T, Shain KH, Siqueira Silva AS, Baz RC, Blue BJ, Grajales-Cruz AF, Hansen DK, Cleveland JL, Perna F, Lynch CC, Binning JM, Atkins RM, Song X, Locke FL, Freeman CL. Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma. Blood. 2026 Jun. Pubmedid: 42275255.
• Ramlal R, Kim J, Thompson Z, Ochoa-Bayona L, Mishra A, Nishihori T, Perez L, Bejanyan N, Castaneda Puglianini O, Faramand R, Mirza S, Khimani F, Lazaryan A, Hansen D, Locke F, Artz A, Sorror M, Pidala J. Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT). Bone Marrow Transplant. 2026 Jun.61(6):702-704. Pubmedid: 41951840.
• Pidala JA, Cieri N, Schell MJ, Song X, Shao Y, Cao B, Du D, Thapa R, Betts BC, Janssen W, Cubitt C, Yoder SJ, O'Leary MF, Beato F, Veerapathran A, Menges MA, Burton M, Bejanyan N, Castaneda-Puglianini OA, Elmariah H, Faramand RG, Fernandez HF, Hansen DK, Jain MD, Khimani F, Lazaryan A, Liu HD, Locke FL, Mirza AS, Mishra A, Nieder M, Nishihori T, Ochoa L, Perez LE, Perna F, Ramlal R, Torres NE, Anasetti C. Expanded antigen-specific donor regulatory T cells for GVHD prevention. Blood. 2026 Jun. Pubmedid: 42322116.
• Rees MJ, Cassano RC, Tan M, Zolotov E, Sidana S, Dima D, Kort J, Afrough A, Gaballa M, Pasvolsky O, Mikkilineni L, Khouri J, Raza S, Zanwar SS, Ferreri CJ, Kumar S, Khan AM, Atrash S, Portuguese AJ, Rana MS, Banerjee R, Freeman C, Blue B, Patel KK, Anderson LD, Puglianini OC, Shune LO, Biran N, Hansen DK, Lin Y. The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma. Am J Hematol. 2026 Jun.101(6):1314-1319. Pubmedid: 41862775.
• Parker NH, Kim J, Bean M, De Vera MT, Carmella R, Duca A, Corallo S, Delgado LC, Merritt E, McCoy J, Brushwood A, Franca M, Hansen DK, Castaneda-Puglianini O, Lazaryan A, Chavez J, Nishihori T, Shah B, Faramand R, Mirza AS, Akhtar O, Peres LC, Figura NB, Jhaveri K, Oswald LB, Jim HSL, Locke FL, Jain M, Freeman CL. Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes. Transplant Cell Ther. 2026 Jun. Pubmedid: 42315024.
• Oswald LB, Li X, Gudenkauf LM, De Avila G, Scheiber-Camoretti D, Small BJ, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Crowder SL, Parker NH, Carson TL, Vinci CE, Baz RC, Shain KH, Blue B, Grajales-Cruz A, Matte K, Kale B, Kaldas D, Perna F, Alsina M, Freeman CL, Castaneda Puglianini O, Nishihori T, Liu H, Locke FL, Jim HSL, Peres LC, Hansen DK. Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma. Bone Marrow Transplant. 2026 Jul.61(7):864-872. Pubmedid: 42115674. Pmcid: PMC13349860.
• Pidala JA, Kim J, Laborde J, Knott S, Mogili K, Zinn J, Monroe AR, Faramand R, Ramlal R, Khimani F, Hansen DK, Torres Luna NE, Jain MD, Perez LE, Mishra A, Ghalehsari N, Castaneda-Puglianini OA, Alsina M, Perna F, Nieder M, Mirza AS, Liu HD, Nishihori T, Ali A, Chellapandian D, Locke FL, Bejanyan N, Anasetti C, Lazaryan A. Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis. Blood Adv. 2026 Jul. Pubmedid: 42480215.
• Hosoya H, Velayati A, Dima D, Jensen A, Portuguese AJ, Hovanky V, Mikkilineni L, Peres LC, Grajales-Cruz AF, Homsy S, Rana MS, Cancilla J, Patil S, Sahaf B, Latchford T, Freeman CL, Scott BJ, Song KW, Castaneda-Puglianini OA, Khan H, Dahiya S, Locke FL, Mackall CL, Miklos DB, Banerjee R, Hansen DK, Alsina M, Sidana S. Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma. Blood. 2026 Jul. Pubmedid: 42418682.
• Gaballa MR, Julian K, Afrough A, Hansen DK, Goel U, De Menezes Silva Corraes A, Dima D, Rana MS, Hosoya H, Mikkilineni L, Fogel L, Raza S, Banerjee R, Zanwar SS, Pasvolsky O, Sannareddy A, Borogovac A, Davis JA, Green K, Biran N, Zolotov E, Herr MM, Shune L, Bhurtel E, DeJarnette S, Atrash S, Ferreri CJ, Richards T, Abid MB, Bal S, Ali HM, Ye JC, Richard S, Kaur G, Shain KH, Castaneda-Puglianini OA, Harada K, De Avila G, Rossi AC, Hassan H, Anderson LD, Voorhees P, Khouri J, Sidana S, Portuguese AJ, Janakiram M, Lee HC, Lin Y, Grajales-Cruz AF, Patel KK, Sborov DW. Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia. Blood Adv. 2026 Jul. Pubmedid: 42392158.
• Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, Smith EC, Skelson L, Matte KL, Blue B, Hovanky VN, Gaballa M, Pasvolsky O, Oswald LB, Fortuna GGM, Wagner CB, DeJarnette S, Dillard C, Perna F, Mikkilineni L, Hosoya H, Freeman CL, Shain KH, Baz RC, Grajales-Cruz A, Puglianini OC, Alsina M, Locke FL, Shune LO, Sborov DW, Patel KK, Sidana S, Hansen DK. Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma. Haematologica. 2026 Jan.111(1):184-195. Pubmedid: 40637727. Pmcid: PMC12775792.
• Rees MJ, Khouri J, Grajales-Cruz AF, Zanwar SS, Goel U, Midha S, Kelley J, Puglianini OC, Corraes AMS, Raza S, Davis JA, Green K, Hansen DK, Banerjee R, Sidana S, Patel KK, Bianchi G, Sborov DW, Lee S, Kumar SK, Baz R, Anwer F, Mikkilineni L, Nadeem O, Lin Y, Anderson LD. The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis. Am J Hematol. 2026 Jan.101(1):187-192. Pubmedid: 41221958.
• Hansen DK, Castaneda Puglianini OA, Grajales-Cruz A, Nagar SP, Ghosh S, Fan L, Alegria V, De Braganca KC, Lengil T, Sharma M, Pai H, Perciavalle M, Emond B, Maitland J, Bixby T, Qureshi ZP, Janakiram M. Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms. Curr Med Res Opin. 2026 Apr.1-9. Pubmedid: 42057607.
• Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025 Oct.146(17):2063-2072. Pubmedid: 40749169.
• Abuhelwa Z, Amisha F, Fan W, De Avila G, Hansen DK, Grajales-Cruz AF, Blue B, Castaneda O, Liu H, Freeman CL, Nishihori T, Locke FL, Shain KH, Baz R, Alsina M. Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease. Front Oncol. 2025 Oct.15:1663814. Pubmedid: 41220935. Pmcid: PMC12597725.
• Afrough A, Dima D, Razzo B, Goel U, Sannareddy A, Pasvolsky O, Vazquez-Martinez MA, Ferreri CJ, Banerjee R, Khouri J, Davis JA, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Anwer F, Shune L, DeJarnette S, Grajales-Cruz AF, Ouchveridze E, De Avila G, Susanibar-Adaniya SP, Portuguese AJ, Schrum D, Eberwein E, Hosoya H, Mikkilineni L, Kaur G, McGuirk JP, Rossi A, Herr MM, Castaneda O, Locke FL, Raza S, Lin Y, Atrash S, Sborov DW, Voorhees PM, Richard S, Garfall AL, Sidana S, Patel KK, Hansen DK, Cowan AJ, Anderson LD, Lee HC. The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience. Blood Cancer J. 2025 Nov.16(1):12. Pubmedid: 41315206. Pmcid: PMC12789570.
• Razzo BM, Midha S, Portuguese AJ, Grajales-Cruz AF, De Menezes Silva Corraes A, Costello P, Liu Y, Sperling AS, Nadeem O, Dima D, Banerjee R, Cowan AJ, Afrough A, Anderson LD, Lieberman-Cribbin A, Kaur G, Goyal A, Atrash S, Ferreri CJ, Voorhees PM, Pasvolsky O, Lee HC, Patel KK, Julian KL, Forsberg PA, Herr MM, Chhabra S, Parrondo RD, Lin Y, Chen A, Susanibar-Adaniya SP, Khouri J, Raza S, Anwer F, Vazquez-Martinez M, Castaneda Puglianini O, Sborov DW, Davis JA, Rossi A, Shune L, Bhurtel J, Hwang WT, Hansen DK, Sidana S, Garfall AL, Richard S. Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium. Blood Cancer Discov. 2025 Nov.6(6):561-571. Pubmedid: 40629516.
• Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Asoori Maringanti S, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD, Richard S, Martin T, Lin Y, Patel KK, Sidana S. Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025 May.43(13):1597-1609. Pubmedid: 39965175. Pmcid: PMC12037312.
• Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V, Beitinjaneh AM, Ouchveridze E, Castaneda Puglianini O, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D, Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH, Kumar AD, Liu Y, Locke FL, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky O, Peres LC, Purvey S, Raza S, Reshef R, Richard S, Rossi AC, Sborov DW, Shune L, Wagner CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, Kumar SK, Lin Y, Martin TG, Voorhees PM, Anderson LD, Cowan AJ, Kaur G. Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. Blood Adv. 2025 May.9(9):2336-2340. Pubmedid: 40088469. Pmcid: PMC12127628.
• Gaballa MR, Castaneda Puglianini O, Cohen AD, Vogl DT, Chung A, Ferreri CJ, Voorhees PM, Hansen DK, Patel KK. BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Adv. 2025 Mar.9(5):1171-1180. Pubmedid: 39729503. Pmcid: PMC11925525.
• Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, Pasvolsky O, Razzo B, Banerjee R, Khouri J, Grajales-Cruz A, Lieberman-Cribbin A, Rana MS, Julian K, DeJarnette S, Portuguese AJ, Gaballa MR, De Avila G, Susaniba Adaniya S, Raza S, Herr MM, Ouchveridze E, Richards T, Hosoya H, Mikkilineni L, Kaur G, Castaneda Puglianini O, Rossi A, Lin Y, Atrash S, Sborov D, Shain KH, Voorhees PM, Richard S, Garfall AL, Hansen DK, Sidana S, Patel KK, Cowan AJ, Anderson LD, Lee HC, Anwer F, Ferreri CJ, Shune L. Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J. 2025 Jun.15(1):111. Pubmedid: 40562770. Pmcid: PMC12198414.
• Dima D, Afrough A, Goel U, Grajales-Cruz A, Khouri J, Julian K, Pasvolsky O, Banerjee R, Razzo B, Ferreri CJ, Vazquez Martinez MA, Davis JA, Sannareddy A, Castaneda Puglianini O, Raza S, Portuguese AJ, Gaballa MR, Rana M, Lieberman-Cribbin A, DeJarnette S, Gonzalez R, Chen A, Herr MM, Mikkilineni L, Hosoya H, Ouchveridze E, Kaur G, Rossi AC, Shune L, Anwer F, Lin Y, Richard S, Sborov DW, Baz RC, Garfall A, Lee HC, Anderson LD, Cowan AJ, Patel KK, Voorhees PM, Sidana S, Susanibar-Adaniya SP, Hansen DK, Atrash S. Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment. Blood Adv. 2025 Jul.9(14):3408-3417. Pubmedid: 40198766. Pmcid: PMC12274829.
• Sweiss K, Wagner C, Anto E, Greene T, Sun R, Gonzalez R, Puglianini OC, Freeman C, Ionescu F, Patel K, Ferreri C, Gaballa M, Shune L, McGuirk J, Sidana S, Hovanky V, Khouri J, Raza S, Anwer F, Dima D, Hashmi H, Davis J, Afrough A, Kaur G, Anderson JL, Forsberg P, Herr M, Hansen DK, Hakan Kocoglu M, Sborov D. Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium. Transplant Cell Ther. 2025 Dec.31(12):989-999. Pubmedid: 40972962.
• Freeman CL, Abraham-Miranda J, Menges M, Atkins RM, Noble J, Liu H, Corallo S, Cuadrado Delgado LA, Ribickas AJ, Savid-Frontera C, de Avila G, Castaneda Puglianini OA, Ochoa-Bayona J, Hansen DK, Alsina M, Baz R, Nishihori T, Shain KH, Locke FL. Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma. Mol Ther. 2025 Aug.33(8):3576-3589. Pubmedid: 40253586. Pmcid: PMC12461620.
• Razzo BM, Midha S, Portuguese AJ, Grajales-Cruz AF, De Menezes Silva Corraes A, Costello P, Liu Y, Sperling AS, Nadeem O, Dima D, Banerjee R, Cowan AJ, Afrough A, Anderson LD, Lieberman-Cribbin A, Kaur G, Goyal A, Atrash S, Ferreri CJ, Voorhees PM, Pasvolsky O, Lee HC, Patel KK, Julian KL, Forsberg PA, Herr MM, Chhabra S, Parrondo RD, Lin Y, Chen A, Susanibar-Adaniya SP, Khouri J, Raza S, Anwer F, Vazquez-Martinez M, Castaneda Puglianini O, Sborov DW, Davis JA, Rossi A, Shune L, Bhurtel J, Hwang WT, Hansen DK, Sidana S, Garfall AL, Richard S. Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium. Blood Cancer Discov. 2025 Aug.OF1-OF11. Pubmedid: 40778675.
• Palfi S, Peres LC, Koelmeyer H, Alsina M, Baz RC, Blue BJ, Corallo S, De Avila G, Freeman C, Gonzalez R, Grajales-Cruz A, Harvey K, Liu HD, Nishihori T, Oliveira GH, Oswald LB, Castaneda Puglianini O, Selvakumar S, Sharma AB, Wang E, Shain KH, Jain M, Locke FL, Alomar M, Hansen DK, Lee DH. Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma. Blood Cancer J. 2025 Apr.15(1):63. Pubmedid: 40229239. Pmcid: PMC11997198.
• Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025 Apr.145(15):1645-1657. Pubmedid: 39652773.
• Kalariya N, Hildebrandt MAT, Hansen DK, Sidana S, Khouri J, Ferreri CJ, Doyle WN, Castaneda Puglianini OA, Freeman CL, Hovanky V, Hosoya H, Shune L, Patel KK. Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv. 2024 Sep.8(17):4679-4688. Pubmedid: 39042903. Pmcid: PMC11402173.
• Handley G, Yepes A, Eliassen E, Dominguez G, Pasikhova Y, Klinkova O, Baluch A, Febres-Aldana AJ, Alsina M, Elmariah H, Khimani F, Hansen DK, Freeman CL, Jain MD, Locke F, Lazaryan A, Liu HD, Mishra A, Mirza AS, Nishihori T, Ochoa L, Perez L, Pidala J, Puglianini OC, Nieder M, Perna F, Kim J, Bejanyan N, Faramand R. Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation. Open Forum Infect Dis. 2024 Oct.11(10):ofae564. Pubmedid: 39411216. Pmcid: PMC11475747.
• Castaneda Puglianini O, Chavez JC. CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies. Semin Hematol. 2024 Oct.61(5):290-296. Pubmedid: 39306480.
• Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024 May.109(5):1514-1524. Pubmedid: 37855036. Pmcid: PMC11063864.
• Akhtar OS, Modi K, Kim J, Skellson L, Smith E, Al-Jumayli MA, Extermann M, De Avila G, Parker N, Castaneda-Puglianini O, Grajales-Cruz A, Baz R, Blue B, Shain K, Alsina M, Liu H, Nishihori T, Jain MD, Locke FL, Hansen DK, Freeman CL. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy. Transplant Cell Ther. 2024 Mar.30(3):283.e1-283.e10. Pubmedid: 38123069.
• Akhtar OS, Sheeba BA, Azad F, Alessi L, Hansen D, Alsina M, Baz R, Shain K, Grajales Cruz A, Castaneda Puglianini O, Liu H, Blue B, Nishihori T, Al Jumayli M, Extermann M, Locke FL, Mhaskar R, Freeman CL. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis. Geriatr Oncol. 2024 Mar.15(2):101628. Pubmedid: 37723045.
• Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024 Jun.17(1):42. Pubmedid: 38845015. Pmcid: PMC11157748.
• Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini OA, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri CJ, Anderson LD, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees PM, Khouri J, McGuirk JP, Sidana S, Hansen DK, Patel KK. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024 Jan.8(1):251-259. Pubmedid: 37855718.
• Hansen DK, Lu X, Puglianini OC, Sorensen S, Usmani SZ, Zhang E, Huo S, Zhang Y, Qureshi ZP, Jagannath S. Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4. Front Immunol. 2024 Aug.15:1408892. Pubmedid: 39234256. Pmcid: PMC11372240.
• Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD, Lin Y. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024 Apr.14(1):63. Pubmedid: 38609386. Pmcid: PMC11015040.
• Oswald LB, Gudenkauf LM, Li X, De Avila G, Peres LC, Kirtane K, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Baz RC, Shain KH, Alsina M, Locke FL, Freeman C, Castaneda Puglianini O, Nishihori T, Liu H, Blue B, Grajales-Cruz A, Jim HSL, Hansen DK. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel. Cancers (Basel). 2023 Sep.15(19). Pubmedid: 37835405. Pmcid: PMC10571575.
• Freeman CL, Atkins R, Varadarajan I, Menges M, Edelman J, Baz R, Brayer J, Castaneda Puglianini O, Ochoa-Bayona JL, Nishihori T, Shain KH, Shah B, Chen DT, Kelley L, Coppola D, Alsina M, Antonia S, Anasetti C, Locke FL. Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. Clin Cancer Res. 2023 Nov.29(22):4575-4585. Pubmedid: 37735756.
• Puglianini OC, Peker D, Zhang L, Papadantonakis N. Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management. Lab Med. 2023 Jan.54(1):13-22. Pubmedid: 35960786.
• Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023 Aug.13(1):117. Pubmedid: 37558706. Pmcid: PMC10412575.
• Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: 37307173. Pmcid: PMC10424134.
• Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, Mishra A, Perez Perez A, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand RG, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022 Jan.6(1):259-269. Pubmedid: 34649279. Pmcid: PMC8753213.
• Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
• Simmons GL, Castaneda Puglianini O. T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments. Cancers (Basel). 2022 Aug.14(17). Pubmedid: 36077787. Pmcid: PMC9455067.
• Crombie JL, Nastoupil LJ, Redd R, Tang K, Shouse G, Herrera AF, Chow VA, Shadman M, Castaneda Puglianini O, Saucier A, Jacobson CA, Armand P, Simmons G. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv. 2021 Sep.5(18):3563-3567. Pubmedid: 34474474. Pmcid: PMC8945592.
• Simmons GL, Satta T, Castaneda Puglianini O. Clinical experience of CAR T cells for multiple myeloma. Best Pract Res Clin Haematol. 2021 Sep.34(3):101306. Pubmedid: 34625232.
• Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma. Drugs Context. 2021 Sep.10. Pubmedid: 34603459. Pmcid: PMC8462994.
• Castaneda-Puglianini O, Chavez JC. Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma. J Blood Med. 2021 Aug.12:775-783. Pubmedid: 34466048. Pmcid: PMC8403007.
• Castaneda Puglianini O, Papadantonakis N. Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts. Ther Adv Hematol. 2020.11. Pubmedid: 32733662. Pmcid: PMC7370557.
• Castaneda O, Baz R. Multiple Myeloma Genomics - A Concise Review. Acta Med Acad. 2019 Apr.48(1):57-67. Pubmedid: 31264433.
• Casas J, Castañeda O, Prezza P, Castillo M, Llosa L. [An unusual presentation of liver involvement in hereditary hemorrhagic telangiectasia biliary disease]. Rev Gastroenterol Peru. 2009 Jul.29(3):266-271. Pubmedid: 19898600.

• Title: DARA-2552: Longitudinal Multi-Center Chart Review Study and Consortium for Multiple Myeloma (eMMpower)
  Award Number: 25-0039
  Sponsor: JOHNSON & JOHNSON
  Hansen, D. (PD/PI), Castaneda P. (Co-PD/PI)